JOP20210015A1 - تركيبات مضادات fcrn وطرق استخدامها - Google Patents

تركيبات مضادات fcrn وطرق استخدامها

Info

Publication number
JOP20210015A1
JOP20210015A1 JOP/2021/0015A JOP20210015A JOP20210015A1 JO P20210015 A1 JOP20210015 A1 JO P20210015A1 JO P20210015 A JOP20210015 A JO P20210015A JO P20210015 A1 JOP20210015 A1 JO P20210015A1
Authority
JO
Jordan
Prior art keywords
compositions
methods
fcrn antibodies
fcrn
antibodies
Prior art date
Application number
JOP/2021/0015A
Other languages
English (en)
Inventor
Eva Williams
Siddhesh Patil
Zhongli Zhang
Louis Gregory St
Narinder Singh
Original Assignee
Momenta Pharmaceuticals Inc
Zhongli Zhang
Louis Gregory St
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc, Zhongli Zhang, Louis Gregory St filed Critical Momenta Pharmaceuticals Inc
Publication of JOP20210015A1 publication Critical patent/JOP20210015A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلّق الاختراع الحالي ويتميّز بتركيبات صيدلانية مستقرة تحتوي على جسم مضاد لـ FcRn.
JOP/2021/0015A 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها JOP20210015A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
JOP20210015A1 true JOP20210015A1 (ar) 2021-01-19

Family

ID=69180697

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2021/0015A JOP20210015A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها
JOP/2021/0014A JOP20210014A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0014A JOP20210014A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها

Country Status (15)

Country Link
US (1) US20210299255A1 (ar)
EP (1) EP3826641A4 (ar)
JP (1) JP7457704B2 (ar)
KR (1) KR20210105872A (ar)
CN (1) CN113301903A (ar)
AU (1) AU2019312139A1 (ar)
BR (1) BR112021001017A2 (ar)
CA (1) CA3106669A1 (ar)
CR (1) CR20210088A (ar)
EA (1) EA202190335A1 (ar)
IL (1) IL280280B1 (ar)
JO (2) JOP20210015A1 (ar)
MX (1) MX2021000790A (ar)
SG (1) SG11202100420UA (ar)
WO (1) WO2020023310A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3250610T3 (da) 2015-01-30 2023-10-30 Momenta Pharmaceuticals Inc Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
CN111712259A (zh) 2017-12-13 2020-09-25 动量制药公司 Fcrn抗体及其使用方法
BR112023021046A2 (pt) * 2021-04-12 2023-12-19 Momenta Pharmaceuticals Inc Composições e métodos para tratamento de miastenia grave pediátrica
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1475101T1 (sl) * 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
AR053026A1 (es) * 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
WO2009062195A2 (en) * 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
DK3250610T3 (da) * 2015-01-30 2023-10-30 Momenta Pharmaceuticals Inc Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
DK3491025T3 (da) 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf

Also Published As

Publication number Publication date
EP3826641A1 (en) 2021-06-02
IL280280B1 (en) 2024-07-01
EA202190335A1 (ru) 2021-06-11
MX2021000790A (es) 2021-07-21
US20210299255A1 (en) 2021-09-30
SG11202100420UA (en) 2021-02-25
AU2019312139A1 (en) 2021-02-04
CA3106669A1 (en) 2020-01-30
CR20210088A (es) 2021-09-02
IL280280A (en) 2021-03-25
JOP20210014A1 (ar) 2021-01-19
BR112021001017A2 (pt) 2021-05-04
KR20210105872A (ko) 2021-08-27
WO2020023310A1 (en) 2020-01-30
CN113301903A (zh) 2021-08-24
JP2021531346A (ja) 2021-11-18
EP3826641A4 (en) 2022-04-20
JP7457704B2 (ja) 2024-03-28

Similar Documents

Publication Publication Date Title
MX2018016364A (es) Anticuerpos anti-pd-l1.
MX2021000790A (es) Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PH12020551716A1 (en) Anti-ror antibody constructs
WO2018234793A3 (en) Antibodies
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
CR20230087A (es) Anticuerpos anti-notch2 y métodos de uso
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.